Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Sarcoma
Study Phase
Phase 3
Study Completion Date
2014-12-31
NCT00354835Uploaded 10-06-2020
Access via NCI by Request
PDS UID: nci-data-431
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) Versus VAC Alternating With Vincristine and Irinotecan (VI) for Patients With Intermediate-Risk Rhabdomyosarcoma (RMS)
Provider Information
Provider Data DescriptionThere are three datasets associated with PubMed ID 30091945: NCT00354835-D1, NCT00354835-D2, and NCT00354835-D3. Dataset NCT00354835-D1 is required for re-creating the main results of the manuscript. The data contains information including histology, group, adverse events, stage, EFS and OS, and demographics.
SponsorChildren's Oncology Group
Data ProviderNational Cancer Institute
Clinical Trials.gov Information
Brief SummaryThis randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed rhabdomyosarcoma. Drugs used in chemotherapy, such as vincristine sulfate, dactinomycin, cyclophosphamide, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiation therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective when given together with radiation therapy in treating patients with rhabdomyosarcoma.
ConditionsAdult Rhabdomyosarcoma
Childhood Alveolar Rhabdomyosarcoma
Childhood Botryoid-Type Embryonal Rhabdomyosarcoma
Childhood Embryonal Rhabdomyosarcoma
Localized Childhood Soft Tissue Sarcoma
Rhabdomyosarcoma
Sarcoma
Stage I Adult Soft Tissue Sarcoma AJCC v7
Stage II Adult Soft Tissue Sarcoma AJCC v7
Stage III Adult Soft Tissue Sarcoma AJCC v7
Intervention TypeDrug: Cyclophosphamide
Biological: Dactinomycin
Drug: Irinotecan Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Questionnaire Administration
Radiation: Radiation Therapy
Drug: Vincristine Sulfate
Drug(s)Drug: Cyclophosphamide
Drug: Vincristine Sulfate
Drug: Irinotecan Hydrochloride
Total Enrolled481
RandomizationRandomized
Blinding MethodNone
Arms InterventionArm I (chemotherapy, radiotherapy) - Active Comparator
Arm II (chemotherapy, radiotherapy) - Experimental
Secondary IDNCI-2009-00427
PubMed (PMID)31174239
30091945
Collaborator(s)National Cancer Institute (NCI)
Region(s)United States
Australia
Canada
New Zealand
Puerto Rico
Switzerland
Age Range49 Years and younger (CHILD, ADULT)
Files: NCT00354835-D1
Data DictionaryNCT00354835-D1-Data-Dictionary_3.pdf
DATANCT00354835-D1-Dataset_3.csv
OTHERREADME.pdf
Files: NCT00354835-D2
Data DictionaryNCT00354835-D2-Data-Dictionary_4.pdf
DATANCT00354835-D2-Dataset_3.csv
OTHERREADME.pdf
Files: NCT00354835-D3
Data DictionaryNCT00354835-D3-Data-Dictionary_4.pdf
DATANCT00354835-D3-Dataset_2.csv
OTHERREADME.pdf
© 2024 Project Data Sphere
All rights reserved
Privacy PolicyTerms of Use